ClinicalTrials.gg
RecruitingNCT05463861Updated Oct 26, 2026

Lemborexant in Delayed Sleep Phase Syndrome

A Phase 4 interventional study of Lemborexant and Placebo in Delayed Sleep Phase Syndrome, sponsored by Stanford University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Stanford University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.

Planned enrollment
21st of 54
86 · median 50
Started
2022
with 4 others
Phase 4
2 of 69
1 open now
Registered
56th of 69
by date
Lead sponsor
3 of 69
Stanford University

Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 21st largest by planned enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2022, is one of 2 in phase 4, and was the 56th registered.

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

Browse Sleep Disorders, Circadian Rhythm studies →

Open to participants now

10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy.

In this 2-year study, we will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.

Read the detailed description

Delayed sleep phase syndrome (DSPS) is a disorder in which a person's sleep is delayed by two hours or more beyond what is considered an acceptable or conventional bedtime. The delayed sleep then causes difficulty in being able to wake up at the desired time.

In DSPS, bedtime is shifted later than the general population such that individuals have difficulty getting enough sleep to meet their sleep needs before they have to get up for their daytime obligations (work, school, childcare, etc.). As a result, patients experience daytime impairment, including daytime sleepiness and cognitive impairment. DSPS, if maintained in adulthood, is associated with numerous deleterious health effects, although causality is not well established. Two phenotypes of DSPS are recognized depending on the phase of entrainment: one with a late phase and normal phase angle (non-circadian) and other with a late phase and abnormal phase angle (circadian). The differentiation of these two phenotypes is theoretical: a mixed situation may be involved in some cases and the exact pathophysiology of each subtype is still controversial.

In theory, however, separating the sample into these two subtypes is likely important to predict short- and long-term responses to orexin antagonists in DSPS.

Lemborexant is one of the dual orexin receptor antagonists on the US market. The purpose of this study is to examine if lemborexant administered 5 to 10 mg nightly, taken at desired bedtime (at least 2 hours prior to self-reported sleep onset time), can improve the symptoms of Delayed Sleep Phase Syndrome both in the circadian and non-circadian phenotypes. The phenotypes will be recruited in 1:1 proportion.The effect of lemborexant will be analyzed based on the collection of information from actigraphy watches, sleep diaries, and sleep scales. The total participation time involved in this study will be approximately 6 weeks (2 weeks of baseline assessment followed by 2-weeks of treatment/placebo, and 2 weeks post-treatment).

03

Conditions studied

  • Delayed Sleep Phase Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older.
  2. Diagnosed with delayed sleep phase syndrome (DSPS) meaning that:

    1. Sleep is delayed by two hours or more beyond what is considered an acceptable or conventional bedtime for the subject (their desired bedtime).
    2. Subjects not able to fall asleep if trying to sleep before the later bedtime;
    3. This is interfering with their wishes/having social impact.
  3. Concomitant medications will be allowed, though dosages will be required to remain fixed throughout participation in the study.
  4. The participant also needs to be willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. depression (PHQ-9 score of 10 or more), anxiety disorder (GAD-7 score of 10 or more), substance use disorder, any other sleep disorder (assessed by the Alliance Sleep Questionnaire- ASQ), or any medical disorder/therapy that could interfere with the trial (this will be verified through interview and analysis of the ASQ).
  2. Use of medications with significant effects on sleep-wake function (insomnia therapies, stimulants)- unless they are discontinued at least 5 half-lives prior to study participation. Non-sedative antidepressants or SSRI will be allowed if at a stable dose in the absence of concomitant severe depression or severe anxiety.
  3. Use of inhibitors and CYP3A inducers, at least 1 week (or five half-lives, whichever is longer) prior to the first day of the baseline phase.
  4. Pregnancy (verified by urine pregnancy test on visits 1, 2, and 3) or plan to become pregnant in the next 3 months or currently breastfeeding.
  5. Shift workers or subjects working unusual hours.
  6. Any risk of suicide within 6 months of screening period or throughout the trial (accessed by the Investigator and by the C-SSRS questionnaire).
  7. Transmeridian travel across more than 3 time zones 4 weeks prior to the screening phase.
  8. Transmeridian travel across more than 2 time zones during this trial (including the screening phase).
  9. Having a positive drug test or being unwilling to refrain from using illegal drugs or marijuana during this trial.
  10. Any clinically abnormal symptom or organ impairment found by medical history at Screening or Baseline and physical examinations, vital signs, findings, or laboratory test results that require medical treatment.
  11. Impaired liver function (values for enzymes (AST) and alanine transaminase (ALT) > 1.5 times the ).
  12. Known to be positive.
  13. Has a corrected using Fridericia's formula interval (QTcF interval) >450 ms demonstrated on repeated ECGs (repeated only if initial ECG showed corrected QT interval (QTc) >450 ms) at Screening or Baseline.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    Lemborexant

    Patients receive Lemborexant 5mg for 7 days and may be dose adjusted to 10mg. Patients continue to take Lemborexant 5mg or 10 mg for an additional 7 days.

    Drug: Lemborexant

  • Placebo comparator
    Placebo

    Patients receive placebo to match Lemborexant for 14 days.

    Drug: Placebo

Interventions

  • Lemborexant tablet administered orally once daily.

    Also known as: dayvigo®

  • DrugPlacebo

    Placebo to match Lemborexant tablet administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Change in actigraphy sleep latency onset

    Sleep latency is the time from laying down until falling asleep. Actigraphy data obtained using Axivity- AX6.

    Time frame: From 2 weeks prior to randomization to 4 weeks post randomization

Secondary outcomes

  1. Change in Epworth Sleepiness Scale (ESS)

    This is a scale to evaluate daytime sleepiness. Range from 0 to 24 points (higher scores mean more sleepiness).

    Time frame: From randomization to 4 weeks post randomization

  2. Change in Karolinska Sleepiness Scale (KSS)

    Self-report for daytime sleepiness with 1 being extremely alert and 10 being extremely sleepy, can't keep awake.

    Time frame: From randomization to 4 weeks post randomization

  3. Change in sleep diary derived sleep onset latency

    Sleep latency is the time from laying down until falling asleep as estimated by patient in dairy.

    Time frame: From 2 weeks prior to randomization to 4 weeks post randomization

  4. Sleep Regularity Index

    Sleep Regularity Index is defined as the percentage probability of a person being asleep (or awake) at any two time points 24 hours apart. Actigraphy data obtained using Axivity- AX6.

    Time frame: From 2 weeks prior to randomization to 4 weeks post randomization

  5. Change in actigraphy derived total sleep time

    Actigraphy data obtained using Axivity- AX6.

    Time frame: From 2 weeks prior to randomization to 4 weeks post randomization

  6. Change in sleep diary derived total sleep time.

    Estimated by patient in dairy.

    Time frame: From 2 weeks prior to randomization to 4 weeks post randomization

  7. Change in mean actigraphy derived wake time

    Wake time is total time awake over night after sleep onset. Actigraphy data obtained using Axivity- AX6.

    Time frame: From 2 weeks prior to randomization to 4 weeks post randomization

  8. Change in mean sleep diary derived wake time

    Wake time is total time awake over night after sleep onset as estimated by patient in dairy.

    Time frame: From 2 weeks prior to randomization to 4 weeks post randomization

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2022 (actual). Primary completion is estimated for May 2027, 63 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jan 2026 → May 2027 and completion Jan 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Jul 19, 2022
StartActual
Feb 1, 2022
Primary completionEst.
May 31, 2027was Jan 2026
CompletionEst.
May 31, 2027was Jan 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Oct 26, 2026
Sites
1 site added. Stanford Univeristy is now Completed
Show site
  • University of California San Francisco · San Francisco, United States
Oct 26, 2026
Primary completion
Jan 21, 2026→May 31, 2027
Oct 26, 2026
Study completion
Jan 21, 2026→May 31, 2027
Oct 26, 2026
Enrollment
71 (actual)→86 (estimated)
Oct 26, 2026
Sponsor
Collaborators added: Eisai Co., Ltd.
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Completed→Recruiting
    1 site added. Stanford Univeristy is now Completed
    Show site
    • University of California San Francisco · San Francisco, United States
    Primary completion Jan 21, 2026→May 31, 2027
    Study completion Jan 21, 2026→May 31, 2027
    Enrollment 71 (actual)→86 (estimated)
    Sponsor Collaborators added: Eisai Co., Ltd.
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05463861
Responsible party
Emmanuel Mignot (Principal Investigator, Stanford University) — Principal investigator
First posted
Jul 19, 2022
Start date
Feb 1, 2022
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Emmanuel Mignot, MD, PhD
principal investigator · Stanford University
Andrew D Krystal, MD, MS
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemborexant

Start the discussion